Leung Kam
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD
Optical fluorescence imaging is increasingly being used to monitor biological functions of specific targets (1-3). However, the intrinsic fluorescence of biomolecules poses a problem when fluorophores that absorb visible light (350–700 nm) are used. Near-infrared (NIR) fluorescence (700–1,000 nm) detection avoids the natural background fluorescence interference of biomolecules, providing a high contrast between target and background tissues in small animals. NIR fluorophores have a wider dynamic range and minimal background fluorescence as a result of reduced scattering compared with visible fluorescence detection. NIR fluorophores also have high sensitivity, attributable to low background fluorescence, and high extinction coefficients, which provide high quantum yields. The NIR region is also compatible with solid-state optical components, such as diode lasers and silicon detectors. NIR fluorescence imaging is a non-invasive alternative to radionuclide imaging in small animals or with probes in close proximity of the target in humans (4, 5). Among the various optical imaging agents, only indocyanine green (ICG), with NIR fluorescence absorption at 780 nm and emission at 820 nm, is approved by the United States Food and Drug Administration for clinical applications in angiography, blood flow evaluation, and liver function assessment. It is also under evaluation in several clinical trials for other applications, such as optical imaging and mapping of both the lymphatic vessels and lymph nodes in cancer patients for surgical dissection of tumor cells and endoscopic imaging of the pancreas and colon. The sentinel lymph node (SLN) is considered to be the first lymph node to receive lymphatic flow from tumor sites and therefore, will contain metastatic tumor cells (6). SLN mapping has been used in diagnosis of metastasis of solid tumors (7). Radical lymph node dissection is performed in patients with malignant cells in the SLNs. Presently, SLN mapping is performed by a combination of radioactive tracer and blue dye, which require a radiologist. The current procedure is also time-consuming and requiring a steep learning curve. NIR quantum dots (QDs) has been studied in SLN mapping in small animals (4, 8). However, there are only limited studies of long-term toxicity of QDs in animals (9). IRDye CW800-CW is an indocyanine-type NIR fluorophore with peak absorption at 775 nm, and peak excitation emission at 796 nm. It provides a quantum yield of 9% with an extinction coefficient of 242,000 Mcm. It has a molecular weight of 962 Da. Human serum albumin (HSA) has been successfully conjugated with IRDye 800CW to form IRDye 800CW-HSA (HSA800) for non-invasive NIR mapping of SLNs in small animals (10-12).
光学荧光成像越来越多地用于监测特定靶点的生物学功能(1-3)。然而,当使用吸收可见光(350-700nm)的荧光团时,生物分子的固有荧光会带来问题。近红外(NIR)荧光(700-1000nm)检测可避免生物分子的自然背景荧光干扰,在小动物体内的靶组织与背景组织之间提供高对比度。与可见荧光检测相比,近红外荧光团具有更宽的动态范围且背景荧光最小,这是由于散射减少所致。近红外荧光团还具有高灵敏度,这归因于低背景荧光以及高消光系数,从而提供高量子产率。近红外区域也与固态光学组件兼容,如二极管激光器和硅探测器。近红外荧光成像在小动物体内是放射性核素成像的非侵入性替代方法,在人体中则是在靶点附近使用探针的非侵入性替代方法(4,5)。在各种光学成像剂中,只有吲哚菁绿(ICG),其在780nm处吸收近红外荧光并在820nm处发射,已被美国食品药品监督管理局批准用于血管造影、血流评估和肝功能评估的临床应用。它也正在几项临床试验中接受评估,用于其他应用,如癌症患者淋巴管和淋巴结的光学成像和测绘,以进行肿瘤细胞的手术切除以及胰腺和结肠的内镜成像。前哨淋巴结(SLN)被认为是第一个接收来自肿瘤部位淋巴流的淋巴结,因此会含有转移性肿瘤细胞(6)。前哨淋巴结测绘已用于实体瘤转移的诊断(7)。在前哨淋巴结中有恶性细胞的患者会进行根治性淋巴结清扫。目前,前哨淋巴结测绘是通过放射性示踪剂和蓝色染料联合进行的,这需要放射科医生。当前的程序也很耗时,并且需要陡峭的学习曲线。近红外量子点(QDs)已在小动物的前哨淋巴结测绘中得到研究(4,8)。然而,关于量子点在动物体内长期毒性的研究仅有有限的一些(9)。IRDye CW800-CW是一种吲哚菁型近红外荧光团,其峰值吸收在775nm,峰值激发发射在796nm。它的量子产率为9%,消光系数为242,000Mcm。其分子量为962Da。人血清白蛋白(HSA)已成功与IRDye 800CW偶联形成IRDye 800CW-HSA(HSA800),用于小动物前哨淋巴结的非侵入性近红外测绘(10-12)。